CETP inhibition clings to life as Roche’s dal-OUTCOMES post mortem proves inconclusive
This article was originally published in Scrip
A shadow continued to fall over cholesterol ester transfer protein (CETP) inhibitors, as the full results of Roche’s doomed dal-OUTCOMES study were presented at the American Heart Association meeting in Los Angeles, suggesting that a small increase in blood pressure with dalcetrapib may have done for the drug
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.